Show simple item record

dc.contributor.authorChakrabarti, D
dc.contributor.authorParker, CC
dc.coverage.spatialSwitzerland
dc.date.accessioned2024-08-02T13:42:30Z
dc.date.available2024-08-02T13:42:30Z
dc.date.issued2024-07-01
dc.identifierS0302-2838(24)02308-X
dc.identifier.citationEuropean Urology, 2024, 86 (1), pp. 18 - 19en_US
dc.identifier.issn0302-2838
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/6335
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.doi10.1016/j.eururo.2024.04.011
dc.identifier.doi10.1016/j.eururo.2024.04.011
dc.formatPrint-Electronic
dc.format.extent18 - 19
dc.languageeng
dc.language.isoengen_US
dc.publisherELSEVIERen_US
dc.relation.ispartofEuropean Urology
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectHumans
dc.subjectMale
dc.subjectProstatic Neoplasms
dc.subjectPatient Selection
dc.subjectAndrogen Antagonists
dc.titleMetastatic Hormone-sensitive Prostate Cancer: Patient Selection for Prostate Radiotherapy.en_US
dc.typeJournal Article
dcterms.dateAccepted2024-04-02
dc.date.updated2024-08-02T13:41:53Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1016/j.eururo.2024.04.011en_US
rioxxterms.licenseref.startdate2024-07-01
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/38677933
pubs.issue1
pubs.organisational-groupICR
pubs.organisational-groupICR/Primary Group
pubs.organisational-groupICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.publisher-urlhttp://dx.doi.org/10.1016/j.eururo.2024.04.011
pubs.volume86
dc.contributor.icrauthorParker, Chris
icr.provenanceDeposited by Mr Arek Surman on 2024-08-02. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S235230422300346X-main.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/